Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ejhf.3787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differences in Efficacy Among New and Old Potassium Binders in Dialysis Patients: A Systematic Review and Meta-Analysis.
G Ital Nefrol
August 2025
Unit of Nephrology and Dialysis, Department of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
Hyperkalemia is a common and serious complication in dialysis patients, with increased incidence and severity over time. Newer potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), offer improved tolerability compared to older agents. This meta-analysis aims to evaluate the efficacy and safety of these newer binders in dialysis patients.
View Article and Find Full Text PDFSodium alginate/polyvinylpyrrolidone/lapatinib-loaded Zr-metal organic framework: biocompatibility evaluation and pH-responsive drug release for oral delivery applications.
J Mater Chem B
September 2025
Department of Chemistry, National Institute of Technology Calicut, 673601, Kerala, India.
Recent advancements in drug delivery systems have transformed drug administration methods to ensure precise, targeted delivery with minimal side effects. Innovations involving polymer-metal organic frameworks can significantly improve drug stability and controlled release properties. In this study, a drug delivery system based on a zirconium metal organic framework (Zr-MOF), sodium alginate (SA), and polyvinylpyrrolidone (PVP) was developed.
View Article and Find Full Text PDFAdverse drug events associated with sodium zirconium cyclosilicate: A real-world pharmacovigilance study based on the FAERS database.
PLoS One
September 2025
Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Sodium zirconium cyclosilicate (SZC, Lokelma) is a novel hyperkalemia therapy, but comprehensive real-world safety data are lacking. This study aimed to characterize SZC-associated adverse events (AEs) using post-marketing surveillance.
Research Design And Methods: AE reports for SZC/Lokelma were extracted from the FDA Adverse Event Reporting System (FAERS) (2004-2023).
A Safe MRI- and PET-guided Method for Increasing Osmotic Blood-Brain Barrier Permeability.
Radiology
September 2025
Department of Diagnostic Radiology and Nuclear Medicine, School of Medicine, University of Maryland, 670 W Baltimore St, Baltimore, MD 21201.
Background Given the current lack of widely adopted strategies for facilitating drug penetration into the brain, developing new techniques to increase blood-brain barrier (BBB) permeability is essential to address the increasing burden of central nervous system disorders. Osmotic blood-brain barrier opening (OBBBO), achieved through intra-arterial delivery of 25% mannitol to the cerebral vasculature, is a pioneering strategy demonstrating both safety and partial efficacy. Purpose To investigate the potential of 25% mannitol with 4% NaCl, a combination that doubles the osmotic power, to safely increase OBBBO efficacy.
View Article and Find Full Text PDFSodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase.
Eur J Heart Fail
August 2025
Late-Stage Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.